|
gptkbp:instanceOf
|
gptkb:psychedelic_phenethylamine
|
|
gptkbp:category
|
gptkb:recreational_drug
|
|
gptkbp:chemicalFormula
|
C12H17NO2
|
|
gptkbp:describedBy
|
gptkb:PiHKAL
|
|
gptkbp:discoveredBy
|
gptkb:Alexander_Shulgin
|
|
gptkbp:drugClass
|
gptkb:amphetamine
psychedelic
|
|
gptkbp:duration_of_effects
|
6-10 hours
|
|
gptkbp:effect
|
euphoria
hallucinations
synesthesia
altered perception
visual enhancement
|
|
gptkbp:firstSynthesized
|
1970s
|
|
gptkbp:hasStreet
|
gptkb:Europa
Aquarust
|
|
gptkbp:IUPACName
|
2-(4-ethyl-2,5-dimethoxyphenyl)ethan-1-amine
|
|
gptkbp:legal_status_in_Canada
|
Schedule III controlled substance
|
|
gptkbp:legal_status_in_United_Kingdom
|
Class A drug
|
|
gptkbp:legal_status_in_United_States
|
Schedule I controlled substance
|
|
gptkbp:meltingPoint
|
208–210 °C (hydrochloride salt)
|
|
gptkbp:molecularWeight
|
207.27 g/mol
|
|
gptkbp:otherName
|
gptkb:2C-E
2,5-dimethoxy-4-ethylphenethylamine
|
|
gptkbp:relatedTo
|
gptkb:2C-T-2
gptkb:2C-B
gptkb:2C-I
|
|
gptkbp:riskFactor
|
adverse psychological reactions
overdose possible
|
|
gptkbp:routeOfAdministration
|
oral
insufflation
|
|
gptkbp:toxicity
|
not well studied
|
|
gptkbp:bfsParent
|
gptkb:F.E.2a
gptkb:NBOMe_series
gptkb:2C_family
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
2C-E
|